{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:22Z","timestamp":1786991962273,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008664","name":"Ono Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007451","name":"Cell Science Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013236","name":"MSD Life Science Foundation, Public Interest Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013236","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jcyt.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T09:36:29Z","timestamp":1634117789000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era"],"prefix":"10.1016","volume":"24","author":[{"given":"Akira","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jcyt.2021.09.004_bib0001","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcyt.2021.09.004_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0003","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jcyt.2021.09.004_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/14712598.2011.601737","article-title":"Novel strategies for blood stem cell mobilization: special focus on plerixafor","volume":"11","author":"Jantunen","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.jcyt.2021.09.004_bib0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/bmt.2010.128","article-title":"The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF","volume":"46","author":"D'Addio","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2021.09.004_bib0007","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.jcyt.2021.09.004_bib0008","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0009","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jcyt.2021.09.004_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.transci.2008.09.012","article-title":"Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients","volume":"39","author":"Mendrone","year":"2008","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0011","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1182\/blood-2005-09-3592","article-title":"AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates","volume":"107","author":"Larochelle","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2021.09.004_bib0012","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/scd.2006.0087","article-title":"Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients","volume":"16","author":"Gazitt","year":"2007","journal-title":"Stem Cells Dev"},{"issue":"4","key":"10.1016\/j.jcyt.2021.09.004_bib0013","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2007-12-130179","article-title":"Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4\/SDF-1 interaction","volume":"112","author":"Devine","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2021.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1537-2995.2011.03525.x","article-title":"Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor","volume":"52","author":"Varmavuo","year":"2012","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0015","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/trf.14182","article-title":"Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes","volume":"57","author":"Worel","year":"2017","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.jcyt.2021.09.004_bib0016","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jca.21496","article-title":"Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure","volume":"32","author":"Worel","year":"2017","journal-title":"J Clin Apher"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"L. International Harmonization Project on, Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2021.09.004_bib0018","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0019","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12185-018-2505-4","article-title":"Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study","volume":"108","author":"Matsue","year":"2018","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.jcyt.2021.09.004_bib0020","first-page":"2267","article-title":"[Appropriate use of granulocyte-colony stimulating factor in treating hematologic malignancies]","volume":"56","author":"Usui","year":"2015","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"10.1016\/j.jcyt.2021.09.004_bib0021","first-page":"61","article-title":"Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines","volume":"34","author":"Keeney","year":"1998","journal-title":"International Society of Hematotherapy and Graft Engineering, Cytometry"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0022","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00277-016-2740-9","article-title":"Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan","volume":"95","author":"Sugimoto","year":"2016","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s12185-020-03007-4","article-title":"Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation","volume":"112","author":"Wada","year":"2020","journal-title":"Int J Hematol"},{"issue":"19","key":"10.1016\/j.jcyt.2021.09.004_bib0024","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"Medical Research Council Adult Leukaemia Working, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcyt.2021.09.004_bib0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"446","key":"10.1016\/j.jcyt.2021.09.004_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0027","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/sj.bmt.1704455","article-title":"Effect of prior chemotherapy on hematopoietic stem cell mobilization","volume":"33","author":"Ford","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2021.09.004_bib0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.transci.2009.05.011","article-title":"Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions","volume":"41","author":"Perseghin","year":"2009","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.jcyt.2021.09.004_bib0029","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jca.21204","article-title":"Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study","volume":"27","author":"Han","year":"2012","journal-title":"J Clin Apher"},{"issue":"7","key":"10.1016\/j.jcyt.2021.09.004_bib0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/14653249.2012.681042","article-title":"Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization","volume":"14","author":"Sancho","year":"2012","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2021.09.004_bib0031","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1600-0609.2006.00644.x","article-title":"The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement","volume":"76","author":"Campbell","year":"2006","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jcyt.2021.09.004_bib0032","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"T. Italian Group for Stem Cell, Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5909","key":"10.1016\/j.jcyt.2021.09.004_bib0033","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jcyt.2021.09.004_bib0034","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI43414","article-title":"Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow","volume":"121","author":"Shiozawa","year":"2011","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.jcyt.2021.09.004_bib0035","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"To","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jcyt.2021.09.004_bib0036","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3324\/haematol.2013.085183","article-title":"Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed\/refractory multiple myeloma","volume":"98","author":"Papanikolaou","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0037","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jcyt.2021.09.004_bib0038","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2021.09.004_bib0039","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21563","article-title":"UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy","volume":"33","author":"Douglas","year":"2018","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.jcyt.2021.09.004_bib0040","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.bbmt.2013.01.005","article-title":"Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells","volume":"19","author":"Maziarz","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0041","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/trf.12434","article-title":"Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients","volume":"54","author":"Varmavuo","year":"2014","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.jcyt.2021.09.004_bib0042","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2018.01.039","article-title":"Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report","volume":"24","author":"Micallef","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2021.09.004_bib0043","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/j.bbmt.2019.05.035","article-title":"Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters","volume":"25","author":"Chen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2021.09.004_bib0044","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ajh.25672","article-title":"Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts","volume":"95","author":"Shah","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.jcyt.2021.09.004_bib0045","first-page":"2219","article-title":"[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study]","volume":"58","author":"Ando","year":"2017","journal-title":"Rinsho Ketsueki"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0046","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/cas.12916","article-title":"Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study","volume":"107","author":"Suzuki","year":"2016","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2021.09.004_bib0047","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2008-03-143677","article-title":"Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population","volume":"112","author":"Vasu","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2021.09.004_bib0048","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbmt.2014.10.007","article-title":"Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis","volume":"21","author":"Hsu","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2021.09.004_bib0049","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jca.21914","article-title":"Race\/ethnicity and underlying disease influences hematopoietic stem\/progenitor cell mobilization response: A single center experience","volume":"36","author":"Uzoka","year":"2021","journal-title":"J Clin Apher"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921007854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921007854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:45:15Z","timestamp":1761443115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324921007854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1465324921007854"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.09.004","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Cell &#38; Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}